Spirit Airline

XpresCheck is a leader in biosurveillance at U.S. airports, collaborating with the Centers for Disease Control and Prevention (CDC) and Concentric by Ginkgo to monitor incoming international travelers for COVID-19 and emerging pathogens. Since its inception, the company has tested over 340,000 participants and expanded its efforts to include wastewater testing, enhancing global genomic surveillance to detect new variants of viruses. Established during the early days of the COVID-19 pandemic, XpresCheck has operated testing facilities at 15 airports across the United States, providing essential health services to travelers. The company's ongoing mission focuses on safety and public health, adapting its strategies based on the evolving landscape of infectious diseases. Generated from the website